



BEYOND MEDICAL
TECHNOLOGIES

Beyond Medical Technologies Inc.
(Formerly Micron Waste Technologies Inc.)

Management Discussion and Analysis
Form 51-102F1

For the six months ended June 30, 2021

August 30, 2021

OVERVIEW

This Management's Discussion and Analysis ("MD&A") is intended to help the reader understand Beyond Medical Technologies Inc. (formerly Micron Waste Technologies Inc.), ("Beyond", "Micron" or the "Company"), its operations, financial performance, current and future business environment and opportunities and risks. This MD&A should be read conjunction with the interim condensed consolidated financial statements for the six months ended June 30, 2021 and the audited consolidated financial statements for the year ended December 31, 2020 and the accompanying notes (the "Financial Statements"), copies of which are filed on the SEDAR website: www.sedar.com.

This MD&A is prepared as of August 30, 2021. All dollar figures stated herein are expressed in Canadian dollars, unless otherwise specified.

The financial information in this MD&A is derived from the Company's Financial Statements prepared in accordance with IFRS. Information provided in this MD&A, including financial information extracted from the Financial Statements, is the responsibility of management. This MD&A may contain forward looking statements based on assumptions and judgments of management regarding events or results that may prove to be inaccurate as a result of risk factors beyond its control. Accordingly, actual results may differ materially from the expected results.

Conflicts of Interest

Certain directors and officers of the Company are, or may become, directors and officers of other companies, and conflicts of interest may arise between their duties as officers and directors of the Company and as officers and directors of such other companies.

DESCRIPTION OF THE COMPANY'S BUSINESS

Beyond Medical Technologies Inc. (formerly "Micron Waste Technologies Inc."), was incorporated on November 29, 2006, pursuant to the *Business Corporations Act*, British Columbia. The registered office of the Company is located at Suite 1500 – 1055 West Georgia Street, Vancouver, B.C. V6E 4N7. Its head office is located at Suite 915 – 700 West Pender Street, Vancouver, B.C. V6C 1G8. On January 12, 2021, the Company's common shares began trading on the Canadian Stock Exchange ("CSE") on January 12, 2021 under the trading symbol "DOCT".

The Company started, in 2020, the business of manufacturing of personal protective equipment ("PPE") mainly medical grade face masks through its newly acquired wholly owned subsidiary, Micron Technologies Inc. (formerly Covid Technologies Inc.), ("Micron Technologies" or "Covid Technologies").

The Company will continue the research and development of its waste digester business in the food and pharmaceuticals industries alongside its PPE business.

OVERALL PERFORMANCE

Investments

On January 13, 2021, the Company entered into a Letter of Intent ("LOI") with Kayan Health Limited ("Kayan Health") to acquire all of the issued and outstanding shares of the latter. As per the Letter of intent with Kayan Health Limited, the Company is required to provide Kayan Health with working capital loan of \$100,000 per month (to a maximum of \$400,000) until the parties have executed a Definitive Agreement.

The agreement was terminated on June 7, 2021.

BEYOND MEDICAL TECHNOLOGIES INC. (Formerly Micron Waste Technologies Inc.)
Management's Discussion and Analysis
As at and for the period ended June 30, 2021

As at June 30, 2021, the Company has advanced \$400,000 to Kayan Health. Upon termination of the LOI, the parties have no further obligations pursuant thereto, except for such continuing obligations as specifically provided for in the LOI, including, but not limited to, the conversion of the \$400,000 previously advanced by the Company to Kayan Health being converted into common shares in the capital stock of Kayan Health in accordance with the terms of the LOI.

As at June 30, 2021, the conversion option of the working capital loan has not been exercised and the Company has reported it as an investment at FVTOCI in accordance with IFRS9. No unrealized gain or loss has been recognized for the period ended June 30, 2021 (2020 – \$Nil).

Financing

On February 5, 2021, the Company closed the first tranche of a non-brokered private placement (the "Private Placement") whereby it issued 10,580,000 units at a purchase price of \$0.125 per unit for gross proceeds of \$1,322,500. Each unit is comprised of one common share in the capital of the Company and one share purchase warrant. Each share purchase warrant will entitle the holder to acquire one common share at a price of \$0.20 per warrant until February 5, 2023.

The Company paid a total of \$875 in cash finders fees ("Finders' Fees") and issued 7,000 finders' warrants ("Finders' Warrants") to an eligible finder. Each Finders' Warrant entitles the holder to purchase one common share ("Finders' Warrant Share") at an exercise price of \$0.20 per Finders' Warrant Share until February 5, 2023.

On March 11, 2021, the Company closed the second and final tranche of the Private Placement whereby it issued 11,619,500 units for gross proceeds of \$1,452,438. Each unit is comprised of one common share in the capital of the Company and one share purchase warrant. Each share purchase warrant will entitle the holder to acquire one common share at a price of \$0.20 per warrant until March 11, 2023.

The Company paid aggregate cash Finders' Fees totalling \$41,746, incurred related legal fees of \$30,557, and issued 333,970 Finders' Warrants. Each Finders' Warrant entitles the holder to purchase one common share at an exercise price of \$0.20 per Finders' Warrant Share until March 11, 2023.

Collectively from both the tranches, the Company issued a total of 22,199,500 units and raised a total net proceeds of \$2,701,759 which will be used for general working capital purposes.

Impact of COVID-19

Since December 31, 2019, the outbreak of the novel strain of coronavirus, specifically identified as "COVID-19", has resulted in government worldwide enacting emergency measures to combat the spread of the virus. These measures, which include the implementation of travel bans, self-imposed quarantine periods and physical distancing, have caused material disruption to business globally resulting in an economic slowdown. Global equity markets have experienced significant volatility and weakness.

The Company's wholly owned subsidiary, Micron Technologies, has been manufacturing and selling three-ply medical grade face masks since August 2020. Micron Technologies' N95 Model 8800 face masks have been approved by Health Canada and the US Food and Drug Administration and have passed testing with Kinetics Analytical and Environmental Laboratories. Micron Technologies has submitted its N95 Model 8800 face masks to the National Institute for Occupational Safety and Health ("NIOSH") for certification. Once certification is obtained, it plans to maximize production efforts of N95 masks.

RESULTS OF OPERATIONS

For six months ended June 30, 2021 vs. June 30, 2020

The Company had a net loss and comprehensive loss of \$1,204,687 for the six months ended June 30, 2021 (June 30, 2020 –\$1,294,682). The Company's sales and gross profit amounted to \$531,899 (2020 - \$Nil) and \$302,423 (2020 - \$Nil), respectively. The Company generated all its operating revenue from sale of PPE equipment

BEYOND MEDICAL TECHNOLOGIES INC. (Formerly Micron Waste Technologies Inc.)
Management's Discussion and Analysis
As at and for the period ended June 30, 2021

through one of its subsidiaries, Micron Technologies. The Company's significant operating expenses included the following:

- Amortization of \$84,950 (2020 – \$56,793)
- Business development of \$449,895 (2020 - \$494,631)
- Consulting fees of \$56,648 (2020 – \$189,064)
- General office and administrative of \$73,504 (2020 - \$42,607)
- Management fees of \$150,000 (2020 - \$156,000)
- Professional fees of \$106,207 (2020 - \$89,391)
- Selling expense of \$325,113 (2020 - \$Nil)
- Share based compensation of \$212,390 (2020 - \$Nil)
- Transfer agent and filing fees of \$22,500 (2020 - \$29,842)

During the period ended June 30, 2021, the Company had realized loss on sale of marketable securities of \$Nil (2020 - \$17,870) and unrealized loss on sale of marketable securities of \$Nil (2020 – \$187,500).

Amortization of \$84,950 (2020 - \$56,793) refers to amortization of various property and equipment as well as the right-of-use asset for the Company's leased property. The increase for the period ended June 30, 2021 is mainly due to the additional amortization brought by new manufacturing acquired during the period.

Business development of \$449,895 (2020 - \$494,631) consists of the expenses in relation to promotional activities to create and expand market presence of the Company. With the acquisition of Covid Technologies last year, the Company infused significant funds in advertising the products of the Company to increase the sales. Therefore, the expenditure was comparatively higher during the period ended June 30, 2020.

Consulting fees of \$56,648 (2020 - \$189,064) consist of the fees paid in relation to corporate and operational advisory services received from various consultants. The amount has significantly decreased from comparative period as the management hired new cost-effective consultants during the current year.

General office and administrative of \$73,504 (2020 - \$42,607) relates to the expense incurred to support Company's day-to-day operational activities. With the acquisition of Covid Technologies, Company's support activities have increased significantly which increased the general office and administrative expenses.

Management fees of \$150,000 (2020 - \$156,000) consist of the fees paid to the companies controlled by the CEO and CFO of the Company as discussed under the heading "Transactions with Related Parties." The fees during the period ended June 30, 2021, was similar to the comparative period.

Professional fees of \$106,207 (2020 - \$89,391) consist of expenses in relation to the Company's financial recording and reporting activities, and legal fees charged by the lawyers. Acquisition of Covid Technologies Inc. has led to the increased compliance for the Company. Please also refer to "Transactions with Related Parties."

Selling expense of \$325,113 (2020 - \$Nil) consist of the fees paid to different online selling platforms and other expenses incurred to make the finished products ready for sell. With the acquisition of Covid Technologies Inc, the Company started selling PPE equipment through various online platforms. Accordingly, there was a significant increase in the selling expenses during the period ended June 30, 2021.

Share based compensation of \$212,390 (2020 - \$Nil) consist of the fair value of the stock options vested during the period. The Company issued stock options to officers, directors and employees of the Company which vested during the period ended June 30, 2021.

Transfer agent and filing fees of \$22,500 (2020 - \$29,842) consists of the expenditures in connection with share capital activities and reporting of the Company. Transfer agent and filing fees during the current period was comparatively similar to the corresponding period during the last year.

BEYOND MEDICAL TECHNOLOGIES INC. (Formerly Micron Waste Technologies Inc.)
Management's Discussion and Analysis
As at and for the period ended June 30, 2021

For three months ended June 30, 2021 vs. June 30, 2020

The Company had a net loss and comprehensive loss of \$397,212 for the three months ended June 30, 2021 (June 30, 2020 – \$735,083). Sales and gross profit during the quarter ended June 30, 2021 amounted to \$268,935 (2020 - \$Nil) and \$178,421 (2020 - \$Nil), respectively. The Company's significant operating expenses included the following:

- Amortization of \$43,050 (2020 – \$28,396)
- Business development of \$132,564 (2020 - \$478,247)
- Consulting fees of \$14,898 (2020 – \$32,000)
- General office and administrative of \$36,111 (2020 - \$20,376)
- Management fees of \$72,000 (2020 - \$78,000)
- Professional fees of \$46,605 (2020 - \$70,262)
- Selling expense of \$213,481 (2020 - \$Nil)
- Transfer agent and filing fees of \$8,100 (2020 - \$23,321)

Amortization of \$43,050 (2020 - \$28,396) refers to amortization of various property and equipment as well as the right-of-use asset for the Company's leased property. The increase for the quarter ended June 30, 2021 is mainly due to the additional amortization brought by new manufacturing equipment acquired during the last year.

Business development of \$132,564 (2020 - \$478,247) consists of the expenses in relation to promotional activities to create and expand market presence of the Company. During the quarter ended June 30, 2021, the Company undertook lesser promotional activities. Accordingly, the business development expenses were lower in comparison to the quarter ended June 30, 2020.

Consulting fees of \$14,898 (2020 - \$32,000) has significantly decreased from comparative period as most of the consulting agreements entered by the Company matured and the management entered into new cost-effective consulting contracts during the last year.

General office and administrative of \$36,111 (2020 - \$20,376) increased because of the Company's expansion strategies and acquisition of Micron Technologies.

Management fees of \$77,000 (2020 - \$78,000) was comparatively similar to the last period.

Professional fees of \$46,605 (2020 - \$70,262) decreased since the Company incurred significant legal fees during the quarter ended June 30, 2020, in relation to the acquisition of Covid Technologies.

Selling expense of \$213,481 (2020 - \$Nil) pertain to sales commissions and charges related to the sales revenue generated from the new subsidiary, Covid Technologies, which was not reported in the comparative period.

Transfer agent and filing fees of \$8,100 (2020 - \$23,321) also decreased as a result of lesser number of share capital transactions undertaken during the quarter ended June 30, 2021.

BEYOND MEDICAL TECHNOLOGIES INC. (Formerly Micron Waste Technologies Inc.)
Management's Discussion and Analysis
As at and for the period ended June 30, 2021

SUMMARY OF QUARTERLY RESULTS

The following table presents unaudited selected financial information for each of the last eight quarters:

	Three Months ended June 30, 2021	Three months ended March 31, 2021	Three months ended December 31, 2020	Three months ended September 30, 2020
Total revenue	268,935	262,964	184,815	23,844
Net loss for the period	397,212	807,475	4,764,858	461,393
Loss per share	0.01	0.01	0.08	0.01

	Three months ended June 30, 2020	Three months ended March 31, 2020	Three months ended December 31, 2019	Three months ended September 30, 2019
Total revenue	-	-	-	-
Net loss for the period	735,083	559,599	3,183,592	681,442
Loss per share	0.02	0.01	0.04	0.01

- (1) The Company had revenue of \$268,964 from its PPE manufacturing business. The loss during the quarter ended June 30, 2021, was comparatively similar to the loss during the quarter ended March 31, 2021.
- (2) The Company had revenue of \$262,964 from its PPE manufacturing business. The decreased loss and comprehensive loss for the quarter ended March 31, 2021, as compared with the quarter ended December 31, 2020, was mainly due to the loss of \$4,240,055 on acquisition of Covid Technologies recognized in the quarter ended December 31, 2020.
- (3) The Company had revenue of \$184,815 from its PPE manufacturing business. The increased loss and comprehensive loss for the quarter ended December 31, 2020, as compared with the quarter ended September 30, 2020, was mainly due to the loss on acquisition of Covid Technologies recognized in the quarter.
- (4) The Company started generating revenue from its new PPE manufacturing business. The decreased loss and comprehensive loss for the quarter ended September 30, 2020, as compared with the quarter ended June 30, 2020, was mainly due to decreases in consulting fees/salaries partially offset by increases in business development expenses and costs of goods sold.
- (5) The increased loss and comprehensive loss for the quarter ended June 30, 2020, as compared with the quarter ended March 31, 2020, was mainly due to increases in business development expenses partially offset by decreases in consulting fees/salaries.
- (6) The decreased loss and comprehensive loss for the quarter ended March 31, 2020, as compared with the quarter ended December 31, 2019, was mainly due to decreases in impairment losses that were recognized for the development assets and deferred assets in the quarter ended December 31, 2019, as a result of the suspension of the Cannavore™ project.
- (7) The increased loss and comprehensive loss for the quarter ended December 31, 2019, as compared with the quarter ended September 30, 2019, was mainly due to impairment losses recognized for the development assets and deferred assets as a result of the suspension of the the Cannavore™ project and the uncertainties pertaining to the viabilities of the Organivore™ and Pharmavore™ projects.
- (8) The decreased loss and comprehensive loss for the quarter ended September 30, 2019, as compared with the quarter ended June 30, 2019, was mainly due to decreases in share-based payment, business development expenses, consulting/salaries expenses and transfer agent and filing fees. The decrease in share-based payment was mainly due to the share-based payment associated with the stock options grant on April 8, 2019, of 1,200,000 stock options to various officers and consultants of the Company whereas there was no options grant in the quarter ended September 30, 2019. The decrease in business development expenses was mainly due to additional expenses associated with the ribbon cutting ceremony at the Company's Innovation Centre official opening in April 2019. The decrease in consulting/salaries expenses could be attributed to the termination of employment of two employees. The decrease in transfer agent and filing fees was due to the additional expenditures associated with the preparation of the annual general meeting that were mainly incurred in the quarter ended June 30, 2019.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they become due. The Company manages its liquidity risk by forecasting cash flows from operations and anticipated investing and financing activities. The Company's objective in managing liquidity risk is to maintain sufficient readily available reserves in order to meet its liquidity requirements.

The Company's operating, investing and financing activities for the period ended June 30, 2021, resulted in a net increase in cash of \$1,081,285 (December 31, 2020 – net decrease of \$2,160,320). As at June 30, 2021, the Company's current assets included cash and cash equivalents of \$1,705,490 (December 31, 2020 - \$624,205), prepaid expenses of \$131,000 (December 31, 2020 - \$104,379), amounts receivable of \$114,142 (December 31, 2020 - \$97,009) and inventory of \$603,137 (December 31, 2020 - \$369,053). The Company's current liabilities include accounts payable and accrued liabilities, due to related parties, taxes payable and current portion of lease liabilities of \$298,515 (December 31, 2020 - \$274,264).

BEYOND MEDICAL TECHNOLOGIES INC. (Formerly Micron Waste Technologies Inc.)
Management's Discussion and Analysis
As at and for the period ended June 30, 2021

	As at June 30, 2021	As at December 31, 2020
Working capital ⁽¹⁾	\$ 2,255,254	\$ 920,382
Deficit	\$ 23,545,581	\$ 22,340,894

Working capital increased by \$1,334,872 during the six months ended June 30, 2021. The increase in working capital could be attributed primarily to the unit Private Placement offering.

At present, the Company generates operating income from its PPE manufacturing business with a gross profit of \$302,423. To maintain its ability to continue as a going concern and to further develop its business, the Company is dependent on external financing to fund its future intended business plan. The Company anticipated the PPE business line to be self-financing once it reached its anticipated sales to support its operational expenses.

The pandemic caused by COVID-19 has not had a direct adverse effect on the business and affairs of the Company. For the Company to have sufficient liquidity to fund its ongoing operations and complete development activities, the Company intends to continue financing its future requirements through a combination of debt and/or equity issuance. There is no assurance that the Company will be able to obtain such financings or obtain them on favourable terms. The Company estimates it will have sufficient capital to continue operations for the upcoming year.

Non-GAAP Financial Measure

The Company uses “working capital” to assess liquidity and general financial strength and is calculated as current assets less current liabilities⁽¹⁾. Working capital does not have any standardized meaning prescribed by IFRS and is referred to as a “Non-GAAP Financial Measure.” It is unlikely for Non-GAAP Financial Measures to be comparable to similar measures presented by other companies.

- (1) Working capital is calculated as current assets (June 30, 2021 - \$2,553,769; December 31, 2020 - \$1,194,646), less current liabilities (June 30, 2021 - \$298,515; December 31, 2020 - \$274,264).

Contingencies

From time to time, the Company and/or its subsidiaries may become defendants in legal actions and the Company intends to take appropriate action with respect to any such legal actions, including by defending itself against such legal claims as necessary. As of the date of this report, the Company is not aware of any material or significant claims against the Company.

OUTSTANDING SHARE DATA

As at June 30, 2021 and the date of this report, the Company has:

	June 30, 2021	August 30, 2021
Issued and outstanding common shares	78,728,841	78,728,841
Warrants outstanding	48,607,070	48,607,070
Stock options outstanding	2,862,500	2,862,500

OFF BALANCE SHEET ARRANGEMENTS

There are no off-balance sheet arrangements.

BEYOND MEDICAL TECHNOLOGIES INC. (Formerly Micron Waste Technologies Inc.)
Management's Discussion and Analysis
As at and for the period ended June 30, 2021

COMMITMENTS

The Company has the following annual commitments:

	2021	2022	2023	2024	2025	Total
Warehouse lease	\$ 47,008	\$ 94,017	-	-	-	\$164,530

SEGMENTED INFORMATION

The Company operates in two business segments with operations and long-term assets in Canada. The two business segments include the manufacture of PPE and the development and commercialization of on-site treatment systems that can turn organic waste into clean water that meets municipal effluent discharge standards. All of the Company's assets and expenditures are located and incurred in Canada. The Company's long-term assets are as follows:

	June 30, 2021		December 31, 2020	
	Waste Treatment	PPE Sector	Waste Treatment	PPE Sector
Restricted cash equivalents	\$ -	\$ 29,164	\$ -	\$ 28,750
Deposits - Long-term	8,100	-	8,100	-
Property and Equipment	99,976	387,637	118,632	350,016
Intangibles	107,786	-	143,715	-
	\$ 215,862	\$ 416,801	\$ 270,447	\$ 378,766

At June 30, 2021, long-term assets of \$416,801 relates to the PPE operating segment (December 31, 2020 - \$378,766) and \$215,862 (December 31, 2020 - \$270,447) relates to the waste treatment operating segment.

Until the acquisition of Covid Technologies Inc. on July 8, 2020, the company operates in one reportable operating segment being the development and commercialization of an on-site treatment system that can turn organic waste into clean water that meets municipal effluent discharge standards. As the operations comprised a single reporting segment, amounts disclosed in the consolidated financial statements for loss for the period ended July 30, 2020, also represent segment amounts. During the period ended June 30, 2021, the Company's net loss per segment is presented as follows:

	Waste Treatment	PPE Sector	Corporate	Total
Revenue	\$ -	\$ 531,899	\$ -	\$ 531,899
Cost of goods sold	-	(229,476)	-	(229,476)
Operating expenses	(84,358)	(488,894)	(933,345)	(1,506,597)
Other (income) expenses	(85)	110	(538)	(513)
Net loss	\$ (84,443)	\$ (186,361)	\$ (933,883)	\$ (1,204,687)

RELATED PARTY TRANSACTIONS

The amounts due to related parties are for amounts due to directors and officers. The balances are unsecured, non-interest bearing and have no specific terms for repayment.

BEYOND MEDICAL TECHNOLOGIES INC. (Formerly Micron Waste Technologies Inc.)
Management's Discussion and Analysis
As at and for the period ended June 30, 2021

As at June 30, 2021, \$35,099 (December 31, 2020 - \$10,000) was due to directors and officers of the Company.

	As at	
	June 30, 2021	December 31, 2020
Company controlled by Chief Executive Officer	\$ 20,000	\$ -
Companies controlled by Directors	15,099	10,000
	\$ 35,099	\$ 10,000

During the period ended June 30, 2021 and 2020, the Company entered into the following transactions with related parties:

	Six months ended	
	June 30, 2021	June 30, 2020
Expenses paid or accrued to directors of the Company, senior officers and companies with common directors:		
Management fees	\$ 150,000	\$ 156,000
Consulting fees	77,793	48,000
Professional fees	6,200	-
Rent	18,000	18,000
Share based payments	99,114	-
	\$ 351,107	\$ 222,000

Management fees were paid or accrued to the following:

	Period ended	
	June 30, 2021	June 30, 2020
Company controlled by CEO	\$ 120,000	\$ 120,000
Company controlled by former CFO	30,000	36,000
	\$ 150,000	\$ 156,000

Consulting fees were paid or accrued to the following:

	Six months ended	
	June 30, 2021	June 30, 2020
Company controlled by Directors	\$ 70,143	\$ 9,000
Company controlled by former corporate secretary	2,500	-
Company controlled by former Director	5,150	39,000
	\$ 77,793	\$ 48,000

Professional fees of \$6,200 for the period ended June 30, 2021 (2020 – \$Nil) were paid or accrued to a company controlled by the former CFO.

Rent of \$18,000 for the period ended June 30, 2021 (2020 – \$18,000) were paid or accrued to a company controlled by the CEO.

BEYOND MEDICAL TECHNOLOGIES INC. (Formerly Micron Waste Technologies Inc.)
Management's Discussion and Analysis
As at and for the period ended June 30, 2021

Share-based payments include the following:

	Six months ended June 30, 2021		Six months ended June 30, 2020	
	Number of options	Share-based payment	Number of options	Share-based payment
Director	350,000	\$ 49,557	-	\$ -
Former CFO	250,000	35,398	-	-
Former Director	100,000	14,159	-	-
	700,000	\$ 99,114	-	\$ -

On January 12, 2021, the Company issued 350,000 stock options to the directors (Harveer Sidhu – 250,000, Hyder Khoja – 100,000), 250,000 stock options to former CFO (Michael Sadhra) of the Company, and 100,000 stock options to a former director (Michael Malana) of the Company.

CHANGES IN ACCOUNTING POLICIES AND CRITICAL ACCOUNTING ESTIMATES

For a detailed summary of the Company's significant accounting policies, the readers are directed to Note 3 of the Notes to the audited consolidated financial statements for the year ended December 31, 2020 that are available on SEDAR at www.sedar.com.

FINANCIAL INSTRUMENTS

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of the inputs used to estimate the fair values. The three levels of the fair value hierarchy are:

- Level 1 – Quoted prices (unadjusted) in active markets for identical assets or liabilities;
- Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and
- Level 3 – Inputs that are not based on observable market data.

The Company classified its financial instruments as follow:

	Financial Assets	Loans and Receivables	Other Financial Liabilities
	Fair Value	Measured at	Measured at
	Through Profit or	Amortized cost	Amortized cost
	loss		
June 30, 2021			
Cash and cash equivalents	\$ 1,705,490	\$ -	\$ -
Accounts receivable	-	114,142	-
Accounts payable and accrued liabilities	-	-	(180,381)
Taxes payable	-	-	(232)
Lease liabilities	-	-	(127,502)
	\$ 1,705,490	\$ 114,142	\$ (308,115)

BEYOND MEDICAL TECHNOLOGIES INC. (Formerly Micron Waste Technologies Inc.)
Management's Discussion and Analysis
As at and for the period ended June 30, 2021

	Financial Assets	Loans and Receivables	Other Financial Liabilities	
	Fair Value Through Profit or loss	Measured at Amortized cost	Measured at Amortized cost	
December 31, 2020				
Cash and cash equivalents	\$ 624,205	\$ -	\$ -	-
Accounts receivable	-	97,009	-	-
Accounts payable and accrued liabilities	-	-	(186,845)	
Lease liabilities	-	-	(165,008)	
	\$ 624,205	\$ 97,009	\$ (351,853)	

Fair Value

The carrying value of receivables and accounts payable and accrued liabilities approximated their fair value due to the short-term nature of these instruments.

PROPOSED TRANSACTIONS

The Company has no proposed transactions as at the date of this MD&A.

RISKS AND UNCERTAINTIES

FINANCIAL RISK

The Company's financial instruments are exposed to certain financial risks, including credit risk, interest risk, liquidity risk, and foreign exchange rate risk.

Credit Risk

Credit risk is the risk of loss associated with a counter party's inability to fulfill its payment obligations. The Company's credit risk is primarily attributable to its cash and cash equivalents and accounts receivable. The Company's accounts receivable is comprised of trade receivables, GST receivable, other receivables and accrued interest receivable from guaranteed investment certificates ("GICs") held with the bank. GST receivable is not a financial instrument as it does not arise from contractual obligations. The Company limits exposure to credit risk on GICs by holding deposits in high credit quality banking institutions in Canada. The Company is not exposed to significant credit risk on its other receivables. The Company does not have any asset-backed commercial paper included in cash.

The Company's trade receivables are subject to the expected credit loss model. While cash and cash equivalents and trade and accounts receivable are also subject to the impairment requirements of IFRS 9 *Financial Instruments*, the identified impairment loss was minimal.

Liquidity Risk

Liquidity risk is the risk that the Company will encounter difficulty in satisfying financial obligations as they become due. The Company manages its liquidity risk by forecasting cash flows from operations and anticipated investing and financing activities. The Company's objective in managing liquidity risk is to maintain sufficient readily available reserves in order to meet its liquidity requirements. All of the Company's financial obligations are due within one year.

BEYOND MEDICAL TECHNOLOGIES INC. (Formerly Micron Waste Technologies Inc.)
Management's Discussion and Analysis
As at and for the period ended June 30, 2021

As at June 30, 2021	Carrying amount \$	Contractual cash flows \$	1 year or less \$	1 -5 Years \$
Accounts payable and accrued liabilities	180,381	180,381	180,381	–
Lease liabilities	127,502	141,026	94,017	47,008
	307,883	369,406	274,398	47,008

Market risk

Market risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices. Market risk comprises three types of risk: interest rate risk, foreign currency risk and other price risks.

(a) Interest Rate Risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The risk that the Company will realize a loss as a result of a decline in the fair value of the cash is limited because of its short-term investment nature. The Company's financial asset exposed to interest rate risk consists of cash and cash equivalents.

(b) Foreign Exchange Rate Risk

The Company is exposed to foreign currency risk to the extent expenditures incurred or funds received and balances maintained by the Company are denominated in currencies other than the CAD (primarily US\$). The Company's exposure to foreign currency risk arises primarily on fluctuations between the Canadian dollar and the US dollar. The exposure to foreign exchange rate risk is considered low. The Company has not entered into any derivative instruments to manage foreign exchange fluctuations.

As at March 31, 2021, a 10% strengthening (weakening) of the Canadian dollar against the US dollar would have increased (decreased) the Company's net loss before taxes by approximately \$1,763 (March 31, 2020 - \$812).

(c) Other Price Risk

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate due to changes in market prices, other than those arising from interest rate risk or foreign currency risk. The Company is not exposed to significant other price risk.

Management of Capital

Capital comprises the Company's shareholders' equity. The Company manages its capital structure and makes adjustments to it, based on the funds available to the Company in order to support its operations and business development. The Board of Directors does not establish quantitative return on capital criteria for management, but rather relies on the expertise of the Company's management to sustain future development of the business.

With its PPE manufacturing business in operation, the Company started generating some operating income. To maintain its ability to continue as a going concern and to further develop its business, the Company is dependent on external financing to fund its future intended business plan. The Company manages the capital structure and makes adjustments to it in the light of changes in economic conditions and the risk characteristics of the underlying assets. In order to maintain or adjust the capital structure, the Company may issue new shares through private placements.

Management reviews its capital management approach on an ongoing basis and believes that this approach, given the relative size of the Company, is reasonable.

There were no changes in the Company's approach to capital management during the period ended March 31, 2021. The Company is not subject to externally imposed capital requirements.

Uninsurable Risks

The business of the Company may not be insurable, or the insurance may not be purchased due to high cost. Should such liabilities arise, they could reduce or eliminate any future profitability and result in increasing costs and a decline in the value of the Company.

Financing and Share Price Fluctuation Risks

The market price of the Company's common shares may be subject to wide fluctuations in response to many factors, including variations in the operating results of the Company and its subsidiaries, divergence in financial results from analysts' expectations, changes in earnings estimates by stock market analysts, changes in the business prospects for the Company and its subsidiaries, general economic conditions, legislative changes, and other events and factors outside of the Company's control. In addition, stock markets have from time to time experienced extreme price and volume fluctuations, which, as well as general economic and political conditions, could adversely affect the market price for the Company's common shares.

Risks Associated with Acquisitions

If appropriate opportunities present themselves, the Company intends to acquire businesses, technologies, services or products that the Company believes are strategic. The Company currently has no understandings, commitments or agreements with respect to any other material acquisition and no other material acquisition is currently being pursued. There can be no assurance that the Company will be able to identify, negotiate or finance future acquisitions successfully, or to integrate such acquisitions with its current business. The process of integrating an acquired business, technology, service or product into the Company may result in unforeseen operating difficulties and expenditures and may absorb significant management attention that would otherwise be available for ongoing development of the Company's business. Future acquisitions could result in potentially dilutive issuances of equity securities, the incurrence of debt, contingent liabilities and/or amortization expenses related to goodwill and other intangible assets, which could materially adversely affect the Company's business, results of operations and financial condition. Any such future acquisitions of other businesses, technologies, services or products might require the Company to obtain additional equity or debt financing, which might not be available on terms favourable to the Company, or at all, and such financing, if available, might be dilutive.

Economic Environment

The Company's operations could be affected by the economic context should the unemployment level, interest rates or inflation reach levels that influence consumer trends and consequently, impact the Company's future sales and profitability.

COVID-19 Pandemic Risk

The COVID-19 pandemic has created a dramatic slowdown in the global economy. The duration of the COVID-19 outbreak and the resultant travel restrictions, social distancing, government response actions, business closures and business disruptions, may all potentially impact the Company's operations and access to capital. As of date, the COVID-19 pandemic has not had a direct adverse effect on the business and affairs of the Company. However, there can be no assurance that the Company will not be further impacted by adverse consequences that may be brought about by the COVID-19 pandemic on global financial markets which may reduce share prices and financial liquidity and thereby severely limit the financing capital available in the waste technology sector.

OTHER MATTERS

Legal proceedings

The Company is not aware of any legal proceedings.

Contingent liabilities

At the date of report, management was unaware of any outstanding contingent liability relating to the Company's activities.

ADDITIONAL DISCLOSURE FOR VENTURE ISSUERS WITHOUT SIGNIFICANT REVENUE

Detailed listings of general and administrative expenses and exploration expenditures are provided in the Financial Statements of the Company.

OTHER REQUIREMENTS

Additional disclosure of the Company's material documents, information circular, material change reports, new release, and other information can be obtained on SEDAR at www.sedar.com.

DIRECTORS

Certain directors of the Company are also directors, officers and/or shareholders of other companies that are engaged in the similar line of business. Such associations may give rise to conflicts of interest from time to time. The directors of the Company are required to act in good faith with a view to the best interests of the Company and to disclose any interest they may have in any project opportunity of the Company. If a conflict of interest arises at a meeting of the board of directors, any director in a conflict will disclose his/her interest and abstain from voting in the matter(s). In determining whether or not the Company will participate in any project or opportunity, the directors will primarily consider the degree of risk to which the Company may be exposed and its financial position at the time.

Effective February 10, 2021, Dr. Bharat Bhushan, resigned as Chief Technology Officer (“CTO”) and as a director of the Company.

Effective February 11, 2021, Mr. Michael Kelly was appointed to the Company’s Board of Directors.

Effective April 13, 2021, Mr. Michael Malana, resigned as Director of the Company and Chair of the Audit Committee. Dr. Hyder Khoja assumed the position of the interim Chair of the Audit Committee until a permanent replacement is appointed.

Effective June 1, 2021, Mike Sadhra resigned as Chief Financial Officer (“CFO”) of the Company.

Effective August 4, 2021, Zara Kanji was appointed as CFO of the Company.

Current Directors and Officers of the Company are as follows:

Kal Malhi, CEO and Director

Zara Kanji, CFO

Hyder Khoja, Director and Audit Chair

Harveer Sidhu, Director

Micheal Charles Kelly, Director